Experience

Constellation Pharmaceuticals, A MorphoSys Company

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Sr. Reasch Specialist

  • Jul 2019 - Present



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• senior scientist at Pfizer/Wyeth

  • Aug 2003 - Apr 2019

  Oncology target identification and validation with CRISPR and RNAi Technology Identify novel oncology targets from chemo-resistant cell lines utilizing phage display technology Identification and characterized compounds that induce autophagy with High Content technology Characterized the Her2 SMIPs (small modular immunopharmaceutical) Developed Assays for siRNA Library screens and target validation Oncology target identification and validation with CRISPR and RNAi Technology Identify novel oncology targets from chemo-resistant cell lines utilizing phage display technology Identification and characterized compounds that induce autophagy with High Content technology Characterized the Her2 SMIPs (small modular immunopharmaceutical) Developed Assays for siRNA Library screens and target validation



Millenium Pharmaceuticals

• Cambridge, MA

• Research Investigator

  • 1998 - 2003

  Investigated mechanism of action of small molecule clinical candidates. Developed cell based assay/pathway assay for HTS/secondary assay for validated druggable targets. Developed a secondary assay to validate the HTS hits for membrane-bond lipid metabolizing enzyme. Optimized solid lawn assay conditions for phase II HTS screen of oncology target. Investigated mechanism of action of small molecule clinical candidates. Developed cell based assay/pathway assay for HTS/secondary assay for validated druggable targets. Developed a secondary assay to validate the HTS hits for membrane-bond lipid metabolizing enzyme. Optimized solid lawn assay conditions for phase II HTS screen of oncology target.